Four Gilead HIV approved new drug Genvoya eligible for Europe, effective, and more secure

Gilead is the absolute leader in the field of AIDS treatment, the company developed the drug Four Stribild (E / C / F / TDF) in 2012 and 2013 have been listed in the United States and Europe the second largest market, greatly simplifying HIV The treatment procedures. This month, the newly developed Four Gilead HIV DRUG Genvoya (E / C / F / TAF) in the United States and the EU regulation have been big news came: the 5th of this month, Genvoya obtain FDA approval; on the 23rd of this month , Genvoya re-approved by the EU:
- The United States, Genvoya crowd is: never received treatment HIV-1 infected adults, aged 12 and older weighing at least 35 kilograms of HIV-1 infection among adolescents, as well as HIV-1 virus is currently being inhibited HIV- 1 adult infection.- EU, Genvoya crowd as: HIV-1 infected adults, aged 12 and older weighing at least 35 kilograms of adolescent HIV-1 infection, the condition does not exist and integrase inhibitors emtricitabine or tenofovir Wei mutations associated with resistance to any.
In clinical trials, Genvoya (E / C / F / TAF) comparable efficacy Stribild (E / C / F / TDF), while improving kidney and skeletal parameters, higher security, a wider application of the crowd, the drug will become Gilead HIV franchise in another Reggie, is a new gospel of global HIV community.